Assessing adriamycin-induced early cardiotoxicity by estimating left ventricular ejection fraction using technetium-99m multiple-gated acquisition scan and echocardiography

Nuclear Medicine Communications

Volumn 32, Issue 5, 2011, Pages 381-385

  Fatima, Nosheen ^a   Zaman, Maseeh Uz ^a   Hashmi, Adnan ^a   Kamal, Shahid ^a   Hameed, Abid ^a  

^a Karachi Institute of Radiotherapy & Nuclear Medicine   (Pakistan)

Author keywords

adriamycin; cardiotoxicity; left ventricular ejection fraction; technetium 99m multiple gated acquisition scan

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; TECHNETIUM 99M;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIAC IMAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE GATED ACQUISITION SCAN; NEOPLASM; SCINTISCANNING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; DOXORUBICIN; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RADIONUCLIDE VENTRICULOGRAPHY; RADIOPHARMACEUTICALS; SODIUM PERTECHNETATE TC 99M; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 79955035031     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328343ceb9     Document Type: Article

References (24)

1. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003; 8:17-24. (Pubitemid 37152053)
2. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17:3333-3355. (Pubitemid 29471562)
3. Romond EH, Perez EA, Bryant J. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Combined analysis of NSABP-B31/NCCTG- N9831. Presented at the American Association of Clinical Oncology Annual Meeting, Orlando 2005, Florida, USA, 13-1 7 May 2005.
4. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23:7685-7696. (Pubitemid 46291833)
5. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987; 19:817-828. (Pubitemid 17144746)
6. Ewer MS, Benjamin RS. Cardiac complications. In: Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. editors. Cancer medicine. Ontario, Canada: BC Decker Inc.; 2000.
7. Fingert H, Varterasian M. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management. AAPS J 2006; 8:89-94.
8. Signal PK, Iliskovic N. Doxorubicin induced cardiomyopathy. N Engl J Med 1998; 339:900-902.
9. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: in a retrospective analysis of three trials. Cancer 2003; 97:2869-2879. (Pubitemid 36605157)
10. Bristow MR. Anthracycline cardiotoxicity. In: Bristow MR, editor. Drug induced heart disease. New York: Elsevier; 1980. pp. 191-215.
11. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11:931-936. (Pubitemid 27425894)
12. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11:325-335.
13. Piver MS, Marchetti DL, Parthasarathy KL, Bakshi S, Reese P. Doxorubicin hydrochloride (adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer 1985; 56:76-80. (Pubitemid 15022857)
14. Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol 2008; 15 (Supp1):S16-S29.
15. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005; 23:8597-8605. (Pubitemid 46211501)
16. Shepherd L, Parulekar W, Trudeau M. Left ventricular function following adjuvant chemotherapy for breast cancer: the ncic ctg ma.5 experience [Abstract 522]. Proc Am Soc Clin Oncol 2006; 24:522.
17. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007; 49:330-352. (Pubitemid 46295436)
18. Batist G, Ramakrishnan G, Sekhar Rao C, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-1454. (Pubitemid 32202552)
19. Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91:710-717. (Pubitemid 10218041)
20. Speyer JL, Green MD, Zeleniuch-Jacquotte A. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10:117-127.
21. Pharmacia and Upjohn Company. Adriamycin RDF (doxorubicin hydrochloride for injection USP) in Physicians' Desk Reference (ed 54). Montvale NJ: Medical Economics Company; 2000. pp. 2408-2410.
22. O'Malley JP Cardiovascular system. In: Thralls JH, Ziessmann HA, editors. Nuclear medicine: the requisites. 3rd ed. Missouri: Mosby; 2006. pp. 450-507.
23. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983; 106:1048-1056. (Pubitemid 14229682)
24. Himelman RB, Cassidy MM, Landzberg JS, Schiller NB. Reproducibity of quantitative two-dimensional echocardiography. Am Heart J 1988; 115:425-431.